CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
AZD8233 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04641299
NCT04641299Phase 2Completed
CompareCT.gov

A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia

AstraZeneca·interventional·Posted Nov 23, 2020·Updated Nov 18, 2022

In Brief

A Phase 2 clinical trial evaluating AZD8233 and Placebo for Dyslipidaemia. Completed, enrolled 119 participants across 19 sites in 3 countries.

Detailed Summary

AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD monitoring in the further clinical development program.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidaemia
CountriesDenmark, Slovakia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 23, 2020
Enrollment StartOct 28, 2020
Primary CompletionJul 20, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.6 years ago

Interventions

AZD8233drug

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Placebodrug

Placebo solution